secwatch.observer — SEC 8-K summary
======================================

Issuer:     Verrica Pharmaceuticals Inc. (VRCA)
CIK:        0001660334
Form:       8-K
Filed at:   2025-12-30T23:59:59+00:00
Accession:  0001193125-25-335824
Event type: leadership
Sentiment:  neutral
Materiality: 0.45
Item codes: 5.02
LLM model:  deepseek-v4-flash:cloud@v2

Verrica appoints Charles Frantzreb to board, grants performance-based options to CEO
--------------------------------------------------------------------------------

- Charles Frantzreb, Partner at Caligan, appointed to board effective Dec 26, 2025; Class III director term to 2027 annual meeting.
- CEO Jayson Rieger granted options for 512,269 shares at $8.21, vesting on stockholder plan amendment and stock price milestones of $15 and $25.
- Interim CFO John Kirby granted 10,000 fully vested RSUs on Dec 23, 2025.
- Frantzreb designated by Caligan under Securities Purchase Agreement dated Nov 23, 2025.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1660334/000119312525335824/0001193125-25-335824-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1660334/000119312525335824/d54232d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-25-335824

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer